ORAMED PHARMACEUTICALS INC.

Listed Company

ORMPCIK 0001176309NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.00M

Net Income

$64.05M

Total Assets

$230.86M

Equity

$199.74M

Shares Out

40.45M

Op. Cash Flow

$-9.14M

Business

ORAMED PHARMACEUTICALS INC. is a pharmaceutical company engaged in research and development of oral delivery solutions for therapeutic proteins, focusing on an oral dosage platform designed to protect proteins through the stomach. It develops and tests oral insulin (ORMD-0801), oral vaccine candidates via joint ventures, and related POD™ delivery technologies, and pursues licensing, royalty and commercialization agreements. Key business activities include R&D and clinical development, joint ventures and licensing/royalty arrangements, and strategic investments. The company pursues regulatory approvals primarily via the U.S. FDA and commercial collaborations in China, Korea and other international markets.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-08-31
REVENUES	2	—	1	3	3
COST OF REVENUE	−2	—	—	—	—
GROSS PROFIT	13,000	—	—	—	—
RESEARCH AND DEVELOPMENT EXPENSES	−6	−6	−9	−28	21
GENERAL AND ADMINISTRATIVE EXPENSES	−9	−6	−8	−14	6
OPERATING LOSS	−15	−13	−16	−41	24
OTHER INCOME, NET	958,000	—	—	—	—
INTEREST EXPENSES (note 12)	—	−853,000	−2	—	—
FINANCIAL INCOME (LOSS), NET (note 17)	89	−2	23	3	—
INCOME (LOSS) BEFORE TAX EXPENSES	75	−16	5	−38	—
TAX EXPENSES	−11	−3	—	−100,000	—
NET INCOME (LOSS)	64	−19	6	−38	23
NON-CONTROLLING INTERESTS	−34,000	−43,000	−437,000	−1	—
COMPANYS STOCKHOLDERS	64	−19	5	−37	23
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	1.53	−0.48	0.14	−0.94	—
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	1.5	−0.48	0.14	−0.94	—
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	41	41	40	39	—
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	42	41	41	39	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	46	54	9	40	—
Short-term deposits (note 2)	11	55	95	112	111
Marketable securities (note 3)	5	3	—	4	8
Investments at fair value (note 4,7)	64	29	58	—	—
Convertible note (note 9)	5	—	—	—	—
Prepaid expenses and other current assets	3	1	537,000	1	—
Total current assets	133	143	163	157	148
Long-term deposits	2,000	2,000	7,000	7,000	—
Marketable securities (note 3)	8	—	2	—	4
Investments at fair value (note 4,7)	10	7	51	—	—
Investment in associate at fair value (note 8)	72	—	—	—	—
Loan to an equity method investee (note 6)	553,000	—	—	—	—
Investment in real estate (note 5)	2	—	—	—	—
Other non-marketable equity securities (note 10)	4	4	—	—	—
Amounts funded in respect of employee rights upon retirement	44,000	32,000	27,000	—	—
Property and equipment, net	586,000	698,000	873,000	815,000	388,000
Operating lease right of use assets	750,000	414,000	694,000	987,000	500,000
Total long-term assets	98	12	58	5	30
Total assets	231	155	221	162	178
Accounts payable and accrued expenses (note 11)	6	5	2	4	5
Payable to related parties (note 20)	652,000	329,000	325,000	1,000	—
Deferred income (note 8)	1	—	—	—	—
Dividend Payable	11	—	—	—	—
Operating lease liabilities	285,000	216,000	267,000	247,000	130,000
Total current liabilities	19	6	53	6	7
Long-term deferred revenues (note 13)	2	4	4	—	—
Long-term deferred income (note 8)	1	—	—	—	—
Employee rights upon retirement	39,000	30,000	28,000	—	—
Operating lease liabilities	540,000	156,000	342,000	647,000	370,000
Dividend Payable	275,000	—	—	—	—
Other liabilities	—	60,000	63,000	—	—
Deferred tax liabilities (note 18)	8	—	—	—	—
Total long-term liabilities	12	4	4	5	4
COMMITMENTS (note 13)	—	—	—	—	—
Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2025 and December 31, 2024; 39,275,006 and 39,919,545 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively)	472,000	480,000	485,000	476,000	459,000
Additional paid-in capital	323	322	321	314	—
Accumulated deficit	−123	−177	−158	−163	−127
Total stockholders equity	200	146	164	152	166
Non-controlling interests	—	−918,000	−928,000	−656,000	157,000
Total equity	200	145	163	151	167
Total liabilities and equity	231	155	221	162	178

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-08-31
Depreciation	121,000	193,000	196,000	58,000	77,000
Exchange differences and interest on deposits	830,000	−3	−2	—	—
Changes in fair value of investments	−86	7	—	—	—
Stock-based compensation	6	4	4	12	3
Gain on amounts funded in respect of employee rights upon retirement	−12,000	−5,000	−3,000	—	—
Change in accrued interest on short-term borrowings	—	−1	1	—	—
Prepaid expenses and other current assets	−998,000	−356,000	852,000	268,000	−586,000
Accounts payable, accrued expenses and related parties	1	4	−2	—	—
Net changes in operating lease	117,000	43,000	8,000	−93,000	—
Deferred revenues	−2	—	−1	—	—
Deferred income	−105,000	—	—	—	—
Liability for employee rights upon retirement	9,000	2,000	7,000	−1,000	3,000
Deferred tax liabilities	8	—	—	—	—
Other liabilities	−60,000	−14,000	—	—	—
Total net cash used in operating activities	−9	−8	−10	−28	−21
Purchase of property and equipment	−9,000	−18,000	−254,000	−496,000	−375,000
Purchase of short-term deposits	−11	−54	−91	−152	−18
Purchase of marketable securities	−10	—	—	—	—
Investments at fair value	−65	−1	—	—	—
Purchase of convertible note	−3	—	—	—	—
Proceeds from redemption of short-term deposits	54	97	110	178	—
Exercise of Closing Penny Warrants and Subsequent Penny Warrants	—	−65,000	—	—	—
Proceeds from loan to an equity method investee	6	—	—	—	—
Loan to investment in equity method	−7	—	—	—	—
Real estate investment	−2	—	−100	−3	—
Equity method investee	−250,000	—	—	—	—
Proceeds from long-term deposits	—	5,000	5	—	—
Proceeds from marketable securities	3	—	—	—	—
Proceeds from long-term investments and marketable securities	40	65	5	—	—
Total net cash provided by investing activities	5	106	−73	30	−24
Repurchase and retirement of common stock	−5	−2	—	—	—
Loans repaid	—	−50	−50	—	—
Tax withholdings related to stock-based compensation settlements	—	−2,000	—	−783,000	—
Total net cash used in financing activities	−5	−52	52	11	103
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	−30,000	−4,000	−54,000	−64,000	—
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	−8	45	−31	13	58
Interest paid	—	2	—	2	563,000
Interest received	5	7	5	—	563,000
2024 Refinancing Tranche A	—	−22	—	—	—
2024 Refinancing Tranche B	—	25	—	—	—
Excise tax for repurchase and retirement of common stock	−15,000	−10,000	—	—	—
Recognition of operating lease right-of-use assets and liabilities	600,000	58,000	—	—	—
Waiver of loan granted to subsidiary	952,000	—	—	—	—
Derecognition of right-of-use asset	—	−26,000	—	—	—
Derecognition of lease liability	—	23,000	—	—	—
Purchases of marketable securities not yet settled	254,000	—	—	—	—
Dividends declared but not yet paid in cash	11	—	—	—	—
Warrants received from Alpha Tau	3	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro